In conclusion, our study suggests that TNFAIP8 is a promising therapeutic target for treating NSCLC and highlights the value of using TNFAIP8 expression levels as a promising biomarker for NSCLC progression. The gene discussed is TNFAIP8; the disease is non-small cell lung carcinoma.